NCT02257684 is a Phase 2 clinical trial of pegcrisantaspase in Acute Lymphoblastic Leukemia, sponsored by Jazz Pharmaceuticals.

Who is sponsoring NCT02257684?

NCT02257684 is sponsored by Jazz Pharmaceuticals.

What drugs are being tested in NCT02257684?

Interventions in NCT02257684: pegcrisantaspase.

What condition does NCT02257684 study?

NCT02257684 studies Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma.

Is NCT02257684 still recruiting?

NCT02257684 is currently terminated. Last updated 6 March 2017.

Are results published for NCT02257684?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-03-06 · How we verify

NCT02257684

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Terminated Phase 2 Results posted Last updated 6 March 2017

What this trial tests

Phase 2 trial testing pegcrisantaspase in Acute Lymphoblastic Leukemia in 4 participants. Terminated before completion.

Timeline

1 September 2014

Primary endpoint
1 February 2015

1 January 2016

Quick facts

Lead sponsor	Jazz Pharmaceuticals
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	1 September 2014
Primary completion	1 February 2015
Estimated completion	1 January 2016
Sites	43 locations across United States

Drugs / interventions tested

pegcrisantaspase — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Lymphoblastic Lymphoma — all drugs for Lymphoblastic Lymphoma →

Sponsor

Jazz Pharmaceuticals — full company profile →

Who can join

Adults 1 to 21, any sex, with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Response Rate in Children & Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase Defined as the Proportion of Subjects Having a Serum Asparaginase Activity (SAA) Level of >= 0.1 IU/mL Following the First IV Dose in Course 1
Time frame: 15 days during Course 1
The Serum Asparaginase Activity 14 Days After the First Infusion of Study Drug and the Adverse Events in All Participants.
Time frame: 1 Year

Sponsor's own description

The purpose of this study is to evaluate the effectiveness,safety, and dosage of pegcrisantaspase in patients with Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.
Zhang P, Sun F, Liu S, Jiang S. · · 2016 · cited 459× · PMID 27369864 · DOI 10.1016/j.jconrel.2016.06.040

Verify or expand the search:

Other recruiting trials for Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting

Other Jazz Pharmaceuticals trials

Trials by the same sponsor.

NCT07533942 — A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma · Phase 2 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
NCT07377539 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants · Phase 1 · not yet recruiting
NCT07282587 — Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma · Phase 2 · recruiting
NCT07233239 — A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02257684 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jazz Pharmaceuticals
Last refreshed: 6 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02257684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing